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Abstract
Background: The most common apolipoprotein E (apoE) gene polymorphism has been found to influence plasma
lipid concentration and its correlation with coronary artery disease (CAD) has been extensively investigated in the
last decade. It is, however, unclear whether apoE gene polymorphism is also associated with increased risk of type
2 diabetes mellitus (T2DM). The knowledge of this study may provide the primary prevention for T2DM and CAD
development before its initiation and progression. Therefore, this study was carried out to determine the
association between apoE gene polymorphism and T2DM with and without CAD and its role in lipid metabolism.
Methods: The case-control study was carried out on a total of 451 samples including 149 normal control subjects,
155 subjects with T2DM, and 147 subjects with T2DM complicated with CAD. The apoE gene polymorphism was
tested by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Univariable and
multivariable logistic regression analyses were used to identify the possible risks of T2DM and CAD.
Results: A significantly increased frequency of E3/E4 genotype was observed only in T2DM with CAD group (p =
0.0004), whereas the ε4 allele was significantly higher in both T2DM (p = 0.047) and T2DM with CAD (p = 0.009) as
compared with controls. E3/E4 genotype was also the independent risk in developing CAD after adjusting with
established risk factors with adjusted odds ratio (OR) 2.52 (95%CI 1.28-4.97, p = 0.008). The independent predictor
of individuals carrying ε4 allele still remained significantly associated with both CAD (adjusted OR 2.32, 95%CI 1.17-
4.61, p = 0.016) and T2DM (adjusted OR 2.04, 95%CI 1.07-3.86, p = 0.029). After simultaneously examining the joint
association of E3/E4 genotype combined with either obesity or smoking the risk increased to approximately 5-fold
in T2DM (adjusted OR 4.93, 95%CI 1.74-13.98, p = 0.003) and 10-fold in CAD (adjusted OR 10.48, 95%CI 3.56-30.79,
p < 0.0001). The association between apoE genotypes on plasma lipid levels was compared between E3/E3 as a
reference and E4-bearing genotypes. E4-bearing genotypes showed lower HDL-C and higher VLDL-C and TG,
whereas other values of plasma lipid concentrations showed no significant difference.
Conclusions: These results indicate that ε4 allele has influence on lipid profiles and is associated with the
development of both T2DM with and without CAD, and furthermore, it increased the risk among the subjects with
obesity and/or smoking, the conditions associated with high oxidative stress.
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Type 2 diabetes mellitus (T2DM) is one of the most com-
mon diseases with a high incidence and prevalence
throughout the world. It affects nearly 4% of the world’s
population and this percentage will supposedly be increas-
ing up to 5.4% by year 2025 [1]. Prevalence of diabetes in
Thai adults as shown by the previous study on Thai popu-
lation was 9.6% (2.4 million population) and the impaired
fasting glucose was 5.4% (1.4 million people). Mean fasting
plasma glucose level by age, sex, and area of residence was
found to be substantially higher in urban population
group than rural [2]. T2DM is also known as a major
independent risk factor for coronary artery disease (CAD)
and is the major cause of morbidity and mortality affecting
people with diabetes. To date, several mechanisms such as
dyslipoproteinemia, obesity, oxidative stress, smoking,
exercise, alcohol intake, and genetic factors have been
identified as risk factors of both T2DM and CAD. Lack of
apolipoprotein E (apoE) gene has been clearly demon-
strated as a leading cause of severe hyperlipidemia and
spontaneous development of atherosclerosis in mammals
[3,4]. However, few studies have been able to demonstrate
an association between T2DM and various single nucleo-
tide polymorphisms (SNPs) [5]. Recently, Zeljko et al.
2011 [6] indicated that apoE gene polymorphism is also
associated with obesity in normal Croatian Roma popula-
tion. Adipocytes in an obese person which are the central
and causal components in T2DM can generate high
amount of biologically active molecules called adipokines
or adipocytokines such as plasminogen activator inhibitor-
1 (PAI-1), resistin, leptin, interleukin-6 (IL-6), and tumor
necrosis factor alpha (TNF-a) [7]. These inflammatory
cytokines inhibit insulin-stimulated glucose metabolism in
skeletal muscles and stimulate gluconeogenesis in hepato-
cytes causing hyperglycemia [8]. Hyperglycemia-induced
oxidative stress results in reducing glucose uptake from
blood by muscle cells and develops into insulin resistance
by decreasing insulin secretion from pancreatic b-cells [9].
Taken these together, increased oxidative stress in hyper-
glycemia and reduced lipid clearance because of apoE
gene polymorphism are effective in developing insulin
resistance and T2DM. In addition, high oxidative stress
can also cause vascular inflammation leading to athero-
sclerosis through several cytokines such as NF-B, TNF-a,
IL-1b, and other proinflammatory cytokines [10]. All of
these factors are one of the underlying causes of metabolic
syndrome [7]. Grundy reported that subjects suffering
from the metabolic syndrome are at 2-fold higher risk of
developing CAD and at 5-fold higher risk of developing
T 2 D M ;h o w e v e r ,p e r s o n ss u f f e r i n gf r o mT 2 D Ma r ea t
3-fold higher risk of developing CAD [11].
ApoE gene is one of the most studied genes which is
responsible for stabilizing and solubilizing circulating
lipoproteins in our body and also responsible for the
development of CAD [10,11]. ApoE acts as a high affinity
ligand for several hepatic lipoprotein receptors such as
low-density lipoprotein receptor (LDLR) and LDL-related
protein (LRP) and is involved in the process of cellular
incorporation of several lipoproteins for transport and
digestion [12]. ApoE is a plasma glycoprotein of 34 kDa
with 299-amino acids associated with several other
plasma glycoproteins, such as high density lipoprotein
(HDL), very low density lipoprotein (VLDL), and chylo-
microns [13]. In humans, apoE gene located on the chro-
mosome at position 19q13.2 has been known to be
polymorphic. SNPs at positions 112 (rs 429358) and 158
(rs 7412) determine three major alleles: ε2 (T to C substi-
tution at position 158), the most common ε3, and ε4( C
to T substitution at position 112); 3 isoforms: ApoE2
(Cys112, 158Cys), ApoE3 (Cys112, 158Arg), and ApoE4
(Arg112, 158Arg); and 6 genotypes having 3 homozygous:
E2/E2, E3/E3, E4/E4, and 3 het e r o z y g o u s :E 2 / E 3 ,E 2 / E 4 ,
E3/E4 [13]. Previous studies have shown that apoE alleles
have influence on the lipid clearance and metabolism in
humans. ApoE ε2 allele has been reported to be asso-
ciated with higher plasma levels of apoE, decreased
plasma levels of LDL cholesterol (LDL-C) and lower risk
of CAD [14] while apoE ε4 is associated with lower
plasma level of apoE, increased plasma levels of total cho-
lesterol (TC), LDL-C, VLDL cholesterol (VLDL-C), and
greater risk of CAD when compared to apoE3 homozy-
gotes [15]. One reason for this impaired clearance by
apoE ε4 leading to pathogenesis of CAD might be that
apoE ε4 binds strongly to LDLR compared to other geno-
types. The resulting high amount of lipid can suppress
the synthesis of LDLR leading to lower clearance of lipo-
protein from our body through LDLR [15]. Other studies
have also supported that apoE ε4 allele is associated with
the risk of CAD [16]. However, according to a recent
meta-analysis, the cardiovascular role of apoE2 is uncer-
tain [17] because of its tendency to increase triglyceride
(TG) level [18]. In addition, apo ε2 homozygote in com-
bination with certain additional disorders may develop
type III familial hyperlipidemia and premature athero-
sclerosis [12]. Consequently, with their ability to affect
lipid levels, the apoE gene polymorphism could be one of
the factors influencing development of both T2DM and
CAD. The prevalence of T2DM and CAD is increasing in
Thai population according tot h ec r o s s - s e c t i o n a lE C G
survey of 1991 in Thai population, which found that the
age-standardized prevalence rate of CAD was 9.9/1000
subjects (men 9.2/1000, women 10.7/1000) [19]. World
Health Organization (WHO) global prevalence of dia-
betes report estimated that by the year 2030, 366 million
people, particularly in developing countries, will be
affected by diabetes [20]. Genetic factors like apoE are
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lipoprotein levels and play a central role in the develop-
ment of CAD. However, it is unclear whether apoE gene
is associated with T2DM. The primary aim of this study
was to demonstrate the influence of the apoE gene poly-
morphism on plasma lipids is notable and is an impor-
tant determinant of T2DM and CAD. Secondarily, this
genetic study might also add more information about a
Thai population beyond traditional risk factors.
Materials and methods
Subjects
The studied subjects were recruited from Siriraj Hospital
in Bangkok province. Full consent forms were signed by
the subjects after the nature and motif of the study was
clearly explained to them. The study protocol was
approved by the Ethics Committee of Clinical Study in
Humans, Faculty of Medicine Siriraj Hospital, Mahidol
University. Questionnaires were used to collect the infor-
mation of family and medical history, alcohol consump-
tion, smoking habits and physical activity. Other clinical
and biochemical data such as dyslipidemia, systolic blood
pressure (SBP) and diastolic blood pressure (DBP) from all
subjects were obtained from clinical and laboratory exami-
nations. Anthropometric data (weight, height) were col-
lected and used for BMI calculation. Obesity was defined
as BMI ≥ 25 kg/m
2 according to WHO suggested criteria
for Asian populations [21]. Dyslipidemic or hyperlipidemic
were defined as when one has level of TC >200 mg/dL,
TG >150 mg/dL, LDL-C >130 mg/dL, HDL-C <40 mg/dL,
TC/HDL-C ratio >4.0 or under medication of lipid lower-
ing drugs. Cigarette smokers were allowed into the study
if they had once smoked even if they were no longer smo-
kers. Alcohol drinkers were defined as those who drank at
least two times a week for more than a year. Physical activ-
ities were defined as exercise for at least 2 to 3 days/week
for at least 30 minutes. Hypertension was defined as blood
pressure above 140/90 mmHg or taking antihypertensive
drugs. These subjects were categorized into three groups:
normal healthy controls, T2DM with and T2DM without
CAD, according to the criteria of American Diabetes
Association Classification 2010 [22], with an age range
from 40-65 years.
T h en o r m a lh e a l t h yc o n t r o lg r o u pc o n s i s t e do f1 4 9
subjects with fasting plasma glucose (FPG) < 100 mg/dL
from among those who were randomly selected after rou-
tine health check-up to screen out those having hyperli-
pidemia, hypertension, history of chest pain, family
history of CAD or any forms of cardiovascular disease,
diabetes mellitus, hepatic and renal diseases, inflamma-
tion, general illness, traumatic injury, endocrine disease,
and other metabolic disorders. Subjects under medication
or drug abusers were also excluded.
T2DM subjects without CAD included 155 subjects.
All subjects fulfilled the diabetes mellitus diagnostic cri-
teria of FPG≥126 mg/dL or were under treatment with
oral antidiabetic drugs. The subjects had no electrocar-
diogram (ECG) and/or angiography abnormalities, no
documented history of CAD and no sign of myocardial
ischemia during exercise. Other exclusion criteria for
this group were possession of type 1 diabetes mellitus,
renal disease, hepatic disease, endocrine disease, and
other metabolic diseases.
T2DM complicated with CAD (T2DM + CAD) subjects
included 147 subjects. Subjects were confirmed CAD by
coronary angiography, with at least 50% stenosis in a
major coronary artery or one of their branches. Subjects
were diagnosed to have diabetes with FPG≥126 mg/dL or
those with drug-treated T2DM. Exclusion criteria included
those having renal disease, hepatic disease, type 1 diabetes
mellitus, any form of endocrine disease or metabolic
disease.
APOE Genotyping
Blood samples were collected in EDTA containing tubes.
Guanidine-HCl precipitation method was performed for
genomic DNA extraction. Genomic DNA was subjected to
polymerase chain reaction (PCR) with primers specific to
apoE gene, sense: 5’ AACAACTGACCCCGGTGGCG 3’,
antisense: 5’ ATGGCGCTGAGGCCGCGCTC 3’,s e n s e :5 ’
CCCACCTGCGCAAGCTGCGC 3’, using thermal cycler
with thermal profile according to Richard et al [23]. In
brief, PCR reaction mixture included 20 pmol of each pri-
mer, 0.3 μg genomic DNA, 10 mM of each dNTP, 10X
PCR buffer, 10% DMSO in a final volume of 50 μL. 10 μL
of PCR products was digested with 0.3 unit of Hha1
enzyme according to the supplier’s recommended proce-
dure (Biolabs New England). The resulted fragments were
then separated on 8% polyacrylamide gel and stained with
ethidium bromide. Bands were compared with 25 bp DNA
marker and the different individual genotypes were sepa-
rated and categorized based on the following band length
criteria: E2/E2: 91, 83, 61; E3/E3: 91, 61, 48, 35; E4/E4: 72,
61, 48, 35; E2/E3: 91, 83, 61, 48, 35; E2/E4: 91, 83, 72, 61,
48, 35 and E3/E4: 91, 72, 61, 48, 35.
Lipid analysis and biochemical determination
Venous blood samples were collected from the patients
after 12 hours of overnight fast. Plasma (TC), TG, HDL-
C, glucose and glycosylated hemoglobin (HbA1c) were
quantified using an automated clinical chemistry analy-
zer and enzyme-based colorimetric lists supplied by
Roche Diagnostics, Germany. LDL-C levels were calcu-
lated using Friedewald formula [24]. VLDL-C level was
obtained by using the following equation, VLDL-C =
(TC - LDL-C - HDL-C) and non-HDL-C level was
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lesterol value as a candidate biometrical equivalent to
apoB 100 in diabetes [25].
Statistical analysis
All statistical analyses were performed with IBM SPSS v1
(IBM corporation, Armonk, New York, US) and Micro-
soft 2010 based Excel (Microsoft, US). All data were
expressed as mean (SEM). One-way analysis of variance
(ANOVA) followed by posthoc Bonferroni multiple com-
parison test was applied to evaluate the mean difference
of the data between three groups (control, T2DM with-
out CAD, and T2DM with CAD). Independent samples
t-tests were applied to evaluate the mean difference in
HbA1c, diabetes duration between T2DM and T2DM
with CAD and lipid profiles between groups. Categorical
data such as sex, hypertension, history of smoking, his-
tory of alcohol drinking, physical activity and dyslipide-
mia were evaluated by Chi-square tests or Fisher’s exact
tests. Allele and genotype difference between groups and
deviations from Hardy-Weinberg equilibrium were tested
by Chi-square tests. The association between diseases
and polymorphism was provided by crude or univariable
logistic regression analysis with unadjusted odds ratio
(OR) and 95% confidence interval (95% CI). The adjusted
OR with 95% CI was used to determine the independent
risk factor for development of diabetes and CAD by mul-
tivariable logistic regression analysis after adjusting for
age, sex, BMI, smoking habits, and physical activity. The
multivariable logistic regression analysis was also
repeated for adjusted OR with 95% CI to determine the
risk of apoE polymorphism combined with obesity and
smoking (joint association) after adjusting for age, sex,
and physical activity. Statistical significance was consid-
ered as p < 0.05.
Results
The baseline characteristics of the study population
All enrolled subjects were Thais recruited from Bangkok
area. The anthropometric and demographic data were
summarized along with the clinical and biochemical
data as shown in Table 1. The data from normal con-
trols were used to compare with the data from T2DM
with and without CAD. A significant age difference was
found between control and T2DM with CAD groups
(p < 0.0001) which particularly signifies that increase in
age could possibly lead to higher chances of developing
CAD. There was also significant sex difference between
controls and CAD (p < 0.0001) due to the high preva-
lence of males among CAD patients. Other clinical data
such as BMI, systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were significantly higher in both
groups when compared to controls. CAD patients had
higher frequencies of smoking (p = 0.033) and lower
levels of physical activity (p = 0.030) as compared to
controls and T2DM patients. Lipid profile data demon-
strated significantly higher levels of TC, LDL-C, VLDL-
C, TG, non-HDL-C and lower level of HDL-C in T2DM
and CAD patients when compared to controls. Patients
with CAD had diabetes for a longer period (p < 0.0001)
a n ds h o w e dn os i g n i f i c a n td i f f e r e n c ei nH b A 1 c( p=
0.151) as compared to the patients without CAD. Blood
glucose levels were also significantly higher in both
groups as compared to the controls (p < 0.0001).
ApoE genotype and allele frequencies
The genotype distribution of both controls and CAD
patients were in Hardy-Weinberg equilibrium except for
T2DM that deviated from the basic norm (p = 0.0001).
This was due to the lower presence of E2/E3 genotype in
diabetic group (Table 2). However, since it was unlikely
that any of the assumptions for Hardy-Weinberg equili-
brium were violated, such a departure was attributed to
chance. E3/E3 is also the most common genotype in Thai
general population. E3/E3 genotype and ε3 allele were
significantly lower (p = 0.003 and 0.010 respectively)
while E3/E4 genotype was significantly higher only in
T2DM with CAD subjects (p = 0.0004). In T2DM sub-
jects, E3/E4 genotype had a tendency to be higher
(19.35% vs. 14.09%) but showed no significant difference
(p = 0.219). In addition, E2/E3 genotype and ε2 allele
were also significantly lower in T2DM patients (p = 0.005
and 0.010, respectively). However, ε4 allele frequency
manifested itself as significantly higher in both T2DM
and CAD patients as compared to the controls (p = 0.047
and 0.009, respectively) (Table 3).
Association of apoE gene polymorphism and diseases
Low lipid clearance property of ε4 allele may possibly
make it an independent risk factor for the development
o fC A Da n dT 2 D M .T h u s ,E 3 / E 4g e n o t y p em a yb et h e
risk factor for development of CAD and/or diabetes. The
univariate analysis was used to determine these associa-
tions according to the genotype and allele frequencies of
apoE gene polymorphism.
Interestingly, E3/E4 genotype increased the risk of
CAD with unadjusted OR 2.78 (95%CI 1.50-5.16, p =
0.0004) and showed no association with T2DM with
unadjusted OR 1.46 (95%CI 0.76-2.81, p = 0.219). The ε4
allele appeared to increase risk of both T2DM and CAD
with unadjusted OR 1.72 (95%CI 0.97-3.06, p = 0.047)
and 2.37 (95%CI 1.36-4.15, p = 0.0009, respectively)
(Table 4). After being adjusted for age, sex, BMI, smoking
habits, and physical activity using multivariable binary
logistic regression analysis as shown in Table 5 the E3/E4
genotype appeared to be the independent risk factor for
development of CAD with adjusted OR 2.52 (95%CI
1.28-4.97, p = 0.008). However, the E3/E4 genotype was
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but the ε4 allele was the independent risk factor of both
T2DM and CAD with adjusted OR 2.04 (95%CI 1.07-
3.86, p = 0.029) and OR 2.32 (95%CI 1.17-4.61, p =
0.016), respectively. The multivariable analysis of apoE4
polymorphism and the risk of T2DM and CAD were also
determined according to anthropometric and demo-
graphic characteristics. Sex (particularly male gender),
age and BMI were also independent risks for CAD but
only BMI was the independent risk for T2DM (Table 5).
From joint association analysis, E3/E4 genotype was found
to further increase the risk for development of diabetes
and CAD when combined with either obesity or smoking
after being adjusted for age, sex, and physical activity. The
risk factor for T2DM increased from adjusted OR 1.42
(95%CI 0.72-2.78, p = 0.310) (Table 5) to adjusted OR 4.93
(95%CI 1.74-13.98, p = 0.003) (Table 6), whereas CAD risk
increased from adjusted OR 2.52 (95%CI 1.28-4.97, p =
0.008) (Table 5) to adjusted OR 10.48 (95%CI 3.56-30.79,
P < 0.0001) (Table 6). However, the number of E3/E4
Table 1 Anthropometric, demographic and clinical data of T2DM with and without CAD compared to normal healthy
controls
Variables Controls (n = 149) T2DM (n = 155) T2DM + CAD (n = 147)
Age (Years) 52.01 (0.62) 51.95 (0.53) 57.56 (0.47)**
Sex (male/female) 49/100 57/98 95/52**
BMI (kg/m
2) 23.84 (0.27) 26.89 (0.31)* 27.49 (0.36)**
SBP (mmHg) 111.54 (1.12) 147.31 (1.76)* 155.46 (1.96)**
DBP (mmHg) 73.11 (0.86) 84.50 (1.01)* 92.26 (1.20)**
Hypertension (%) - 73.54 93.19
Smokers (%) 3.35 4.51 9.52
†
Alcohol consumer (%) 23.80 25.50 32.70
Physical activity (%) 68.70 67.09 56.46
†
Diabetes duration (Years) - 6.09 (0.37) 9.07 (0.62)
Glucose (mg/dL) 89.7 (0.64) 225.9 (6.41)* 192.9 (6.55)**
HbA1c (%) - 8.94 (0.16) 8.60 (0.17)
Triglyceride (mg/dL) 98.23 (3.68) 221.1 (10.35)* 204.3 (8.70)**
TC (mg/dL) 191.52 (1.80) 237.76 (5.47)* 202.48(4.19)
†
LDL-C (mg/dL) 111.31(1.76) 146.65(4.84)* 122.36(3.93)
†
HDL-C (mg/dL) 60.17 (1.23) 50.42 (1.27)* 44.59 (0.95)**
VLDL-C (mg/dL) 19.65 (0.73) 45.86 (2.67)* 40.86 (1.74)**
Non-HDL-C (mg/dL) 131.35 (1.95) 182.26 (4.46)* 157.88 (4.09)**
TC/HDL-C 3.4 (0.1) 4.9 (0.2)* 4.8 (0.1)**
Dyslipidemia (%) - 85.2 100
Data are presented as mean values (SEM), or numbers (n) and percentage of subjects. *p-value < 0.0001 in comparison between controls and T2DM, **p-value <
0.0001 in comparison between controls and T2DM + CAD, †p-value < 0.05 in comparison between controls and T2DM + CAD. BMI: body mass index; SBP: systolic
blood pressure; DBP: diastolic blood pressure; HbA1c: hemoglobin A1c; TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; TG: triglyceride; HDL-C:
high density lipoprotein cholesterol; VLDL-C: very low density lipoprotein cholesterol.
Table 2 Frequency distribution of apoE genotypes and alleles in Hardy-Weinberg Equilibrium
Genotype Controls (n = 149) T2DM (n = 155) T2DM + CAD (n = 147)
E2/E2 2 (1.34%) 1 (0.64%) 1 (0.68%)
E3/E3 113 (75.83%) 117 (75.48%) 88 (59.86%)
E4/E4 1 (0.67%) 4 (2.58%) 1 (0.68%)
E2/E3 12 (8.05%) 2 (1.29%) 11 (7.48%)
E2/E4 0 (0%) 1 (0.64%) 0 (0%)
E3/E4 21 (14.09%) 30 (19.35%) 46 (31.29%)
p-value 0.198 0.0001 0.157
Allele ε2(95% CI) 0.05(0.03 - 0.08) 0.02(0.01 - 0.04) 0.04(0.02 - 0.07)
Allele ε3(95% CI) 0.87(0.82 - 0.90) 0.86(0.81 - 0.89) 0.79 (0.74 - 0.83)
Allele ε4(95% CI) 0.07(0.05 - 0.11) 0.13 (0.09 - 0.16) 0.16 (0.12 - 0.21)
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T2DM with and without CAD was small; thus the statisti-
cal power of this joint association comparison is limited.
Relationship between Lipid profiles and apoE4-bearing
genotypes
The significant differences in apo E distribution among
these three groups are mainly due to the differences in
frequencies of the ε4 allele. These distributions in apo
ε4 allele frequencies may lead to the differences in
plasma lipid levels. To test this hypothesis, we analyzed
the correlation between apoE4 and plasma lipid levels
(Table 7). There were no significant differences between
E4 carriers (E2/E4, E3/E4, E4/E4) and E3/E3 genotype
as a reference for all values of plasma lipid levels in
both control and T2DM with CAD. In T2DM group,
there were significant elevation in the values of VLDL-C
and TG but there were no significant differences in TC,
LDL-C, HDL-C and non-HDL-C levels in E4 carriers.
After pooling the overall subjects, the results showed
that E4 carrier has significantly elevated VLDL-C and
TG levels while HDL-C concentration was significantly
decreased as compared to E3/E3.
Discussion
It has been reported that dyslipidemia or dyslipoproteine-
mia might strongly contribute towards aggravating the
problems of micro- and macroangiopathic complications
in diabetic patients [26,27]. This implication was mainly
characterized by higher prevalence of male gender, older
age, smoking habits, and less physical activity. Other dif-
ferences were duration of diabetes, lower levels of HDL-C
and hypertension when compared to those without CAD
which were similar to this study. However, some studies
have also shown that elevation of TG and non-esterified
fatty acid (NEFA) levels accelerated the pathogenesis of
T2DM [28-30]. This suggests that dyslipidemia is asso-
ciated with both T2DM and CAD. Genetic factors which
have strong impact on the metabolism of plasma lipid
have been studied regarding the potential effect of T2DM
and cardiovascular outcomes in various diabetic and non-
diabetic subjects. These studies have underscored that
Table 3 Genotype and Allele frequencies distribution of apoE gene polymorphism in controls, T2DM with and without
CAD compared to healthy controls
Genotype Groups
Controls (n = 149) T2DM (n = 155) T2DM + CAD (n = 147)
E2/E2 0.013 0.006 0.006
E3/E3 0.758 0.754 0.598**
E4/E4 0.007 0.025 0.007
E2/E3 0.080 0.012* 0.074
E2/E4 0 0.006 0
E3/E4 0.140 0.193 0.321***
Allele ε2 0.05 0.02* 0.04
Allele ε3 0.87 0.86 0.79**
Allele ε4 0.07 0.13* 0.16
††
*p-value < 0.01 compared between controls and T2DM, **p-value < 0.01, ***p-value < 0.001 compared between controls and T2DM + CAD.
Table 4 Associations of apoE gene polymorphisms with the risk of T2DM and CAD compared to healthy controls
represented as unadjusted OR
Genotype Controls
(n = 149)
T2DM
(n = 155)
Unadjusted OR
(95% CI)
p-value T2DM + CAD
(n = 147)
Unadjusted OR
(95% CI)
p-value
E2/E2 2 1 0.48 (0.02 - 6.78) 0.616 1 0.50 (0.02 - 7.16) 1.000
E3/E3 113 117 0.98 (0.56 - 1.71) 0.942 88 0.48 (0.28 - 0.81) 0.003
E4/E4 1 4 3.92 (0.41 - 93.19) 0.371 1 1.01(0.06 - 16.36) 1.000
E2/E3 12 2 0.15 (0.02 - 0.72) 0.005 11 0.92(0.36 - 2.33) 0.854
E2/E4 0 1 - 1.000 0 - -
E3/E4 21 30 1.46 (0.76 - 2.81) 0.219 46 2.78(1.50 - 5.16) 0.0004
Allele ε2 16 5 0.29 (0.09 - 0.85) 0.011 13 0.81(0.36 - 1.81) 0.580
Allele ε3 259 266 0.91 (0.56 - 1.48) 0.691 234 0.57(0.36 - 0.90) 0.107
Allele ε4 23 39 1.72 (0.97 - 3.06) 0.047 49 2.37(1.36 - 4.15) 0.0009
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significant variation in lipid profile in our body [31]. ApoE
gene is one of the most widely studied candidate genes for
CAD or any other form of cardiovascular disease and/or
diabetes. A significant relationship of apo E polymorphism
and CAD has been observed in several ethnic groups,
including Caucasian in the USA [32], Austrian [33], Fin-
nish [34], Italian [35], Turkish [36], Indian [37] and Chi-
nese [38] populations. Some studies have shown apoE ε4
allele as an independent risk factor after further adjust-
ment of other established risk factors for development of
CAD in T2DM [16] and myocardial infraction [37]
patients. However, no independent association was
observed after adjusting for age, sex, smoking, BMI, HDL-
C and TG in African- Americans and Caucasians [39].
Therefore, it is of great interest to study the independent
risk factors of this gene polymorphism in a Thai popula-
tion. The present study also coincides with a previous
study regarding the development of CAD in T2DM sub-
jects indicating that the frequency of ε4a l l e l ei ss i g n i f i -
cantly higher in CAD compared to controls and can be
one of the factors for the progression of CAD disease [40].
The frequencies of apoE allele and genotype vary between
different populations [13]. In this study, ε3 allele was the
most frequent allele in control, diabetes, and CAD sub-
jects, while ε2 was less frequent. E3/E3 genotype was the
most frequent isoform found in all groups compared to
the other genotypes which corresponds to previous reports
[13,41]. Additionally, the higher frequency of E3/E4 geno-
type was observed only in CAD (p = 0.0004), whereas the
higher frequency of ε4 allele was observed in both T2DM
and CAD (p = 0.047, p = 0.0009, respectively). From this
study we can conclude that among these selected apoE
alleles (ε2, ε3, and ε4), ε4 allele is one of the predictors of
both diseases in Thai subjects. In addition, the PDAY
(Pathobiological Determinants of Atherosclerosis in
Youth) study reported that individuals with E2/E3 geno-
type had fewer atherosclerotic lesions, whereas those with
t h eE 3 / E 4h a dm o r el e s i o n si nt h ea b d o m i n a la o r t a[ 4 2 ] .
These observations strongly suggest that the ε2 allele has a
protective role against atherosclerosis. However, in this
study, we found that E2/E3 genotype and ε2 allele were
also significantly lower in T2DM group indicating that the
protective effect of ε2 allele on the development of hyperli-
pidemia might be less in T2DM patients. It is probable
that other environmental and genetic factors are involved
in the pathogenesis of CAD.
This present study is the first report to demonstrate
that the ε4 allele containing genotypes is the major pre-
dictor of development of both T2DM and CAD. Our
study also shows strong association of E3/E4 genotype
with development of CAD in T2DM patients (Table 4) as
reported in previous studies [16,42]. After adjusting for
age, sex, smoking, BMI, and physical activity, E3/E4 con-
taining subjects showed 2.52-fold higher risk (p = 0.008)
while ε4 allele containing genotypes led to a 2.32-fold
Table 5 Association of apoE gene polymorphism with the risk of T2DM and CAD compared to healthy controls
represented as adjusted OR
T2DM T2DM + CAD
Adjusted OR (95% CI)
†† p-value Adjusted OR (95% CI)
†† p-value
E3/E4 genotype 1.42 (0.72 - 2.78) 0.310 2.52 (1.28 - 4.97) 0.008
††
ε4 allele 2.04 (1.07 - 3.86) 0.029
†† 2.32 (1.17 - 4.61) 0.016
††
Age 1.00 (0.97 - 1.04) 0.887 1.13 (1.08 - 1.18) <0.0001
Sex 1.29 (0.77 - 2.14) 0.326 3.10 (1.75 - 5.49) <0.0001
BMI 3.68 (2.25 - 6.00) <0.0001 3.66 (2.09 - 6.39) <0.0001
Smoking 2.58 (0.87 - 7.66) 0.086 0.59 (0.13 - 2.50) 0.473
Physical activity 0.68 (0.40 - 1.19) 0.148 0.67 (0.36 - 1.24) 0.206
††After adjusting for age, sex, BMI, smoking habit and physical activity. Normal reference ranges of clinical and biochemical data are described in materials and
methods.
Table 6 Joint association study to evaluate the risk of T2DM and CAD compared to controls
Genotype Obesity/Smoking Controls T2DM Adjusted OR (95% CI)
†† p-value T2DM + CAD Adjusted OR (95% CI)
†† p-value
E3/E3 Neither 70 34 1 - 30 1 -
E3/E3 Either 40 73 3.65 (2.07 - 6.43) <0.0001 56 2.24 (1.15 - 4.35) 0.018
E3/E3 Both 2 10 10.05 (2.06 - 48.96) 0.004 1 2.02 (0.16 - 25.01) 0.585
E3/E4 Neither 14 14 1.97 (0.84 - 4.64) 0.118 7 1.02 (0.34 - 3.06) 0.970
E3/E4 Either 6 15 4.93 (1.74 - 13.98) 0.003 36 10.48 (3.56 - 30.79) <0.0001
E3/E4 Both 6 1 - - 3 - -
†† After adjusting for age, sex and physical activity. Normal reference ranges of clinical and biochemical data are described in materials and methods.
Chaudhary et al. Cardiovascular Diabetology 2012, 11:36
http://www.cardiab.com/content/11/1/36
Page 7 of 11Table 7 Fasting lipid concentration according to apoE4-bearing genotypes
Control T2DM T2DM + CAD Total
Variables (mg/dL) E3/E3 E4-bearing genotypes E3/E3 E4-bearing genotypes E3/E3 E4-bearing genotypes E3/E3 E4-bearing genotypes
(n = 113) (n = 22) (n = 117) (n = 35) (n = 88) (n = 47) (n = 318) (n = 104)
TC 191.58 (2.02) 194.09 (5.22) 232.80 (5.33) 234.77 (8.65) 206.52 (5.26) 192.04 (7.96) 210.88 (2.72) 206.86 (5.11)
LDL-C 110.87 (1.97) 118.52 (4.45) 145.14 (4.54) 140.91 (8.43) 125.33 (4.84) 113.80 (7.33) 127.48 (2.39) 123.92 (4.59)
HDL-C 60.07 (1.43) 55.77 (2.51) 50.84 (1.13) 48.63 (2.98) 45.49 (1.27) 42.70 (1.37) 52.64 (0.81) 47.46 (1.37)**
VLDL-C 20.04 (0.87) 20.18 (1.69) 41.38 (1.99) 55.77 (5.85)* 41.25 (2.37) 38.91 (3.04) 33.76 (1.17) 40.62 (2.72)**
TG 100.20 (4.33) 100.91 (8.48) 206.92 (9.99) 278.83 (29.63)* 206.26 (11.78) 194.53 (15.21) 168.82 (5.88) 203.10 (13.62)**
Non-HDL-C 131.50(2.16) 138.32(4.99) 181.97(5.36) 186.14(8.12) 161.03(5.24) 149.34(7.44) 158.24 (2.83) 159.39 (4.82)
E4-bearing genotypes = E3/E4, E4/E4, E2/E4. Independent sample t-test test was applied to compare between E3/E3 and E4-bearing genotypes. Data are presented as mean values (SEM).
*p-value < 0.05 in comparison between E3/E3 and E4-bearing genotypes in T2DM.
**p-value < 0.01 in comparison between E3/E3 and E4-bearing genotypes in total subjects.
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1higher risk (p = 0.016) for developing CAD and ε4 allele
containing genotypes led to a 2.04-fold higher risk (p =
0.029) in the development of T2DM as compared to the
controls. This signifies that other risk factors have no
influence in development or curbing the disease, suggest-
ing that ε4 allele is the independent risk factor for both
T2DM and CAD. However, E3/E4 genotype further
increases the risk for the development of diabetes and
CAD when combined with smoking and/or obesity
( T a b l e6 ) .T h i sc o n f i r m st h efindings that progression
and development of diabetes and CAD is the conse-
quence of multifactorial parameters, for example, obesity,
smoking, oxidative stress, defect in pancreatic b-cells,
alcohol consumption, exercise, hypertension and genetic
factors. In addition, incidence of T2DM is also subject to
gene-environment interactions, for example, dietary fac-
tors, intake of vegetable fat, polyunsaturated fatty acid,
dietary fiber (particularly cereal fiber), magnesium, and
caffeine were significantly inversely correlated and
intakes of trans fat, saturated fatty acid and heme-iron,
glycemic index, and glycemic load were significantly posi-
tively correlated with the incidence of T2DM [43]. Simi-
larly, regular exercise has been shown to reduce weight,
BMI, HDL-C and insulin resistance. This indicates that
exercise is also associated with decrease risk of T2DM
and CAD. Furthermore, apoE gene polymorphism has
been shown to modulate the effects of exercise on lipo-
protein concentrations in plasma [44]. In this study,
smoking and obesity are shown to be the two major con-
tributing factors that can promote the development of
T2DM and CAD or both when placed in joint association
(Table 6). The reason for this is that smoking and obesity
enhance the oxidative stress which results in decreased
insulin secretion from pancreatic b-cell and decreased
uptake of blood glucose into the muscle cells [9,10]. This
evidence was supported by the experimental study on
atherosclerosis-susceptible B6 (B6.apoE -/-) and athero-
sclerosis-resistant BALB (BALB.apoE -/-) mice that
showed defects in insulin secretion rather than defects in
insulin resistance which explains the mark difference in
susceptibility to T2DM [45]. Moreover, oxidative stress
also increases vascular inflammation leading to CAD
and/or any form of cardiovascular disease with or with-
out combination of T2DM [46].
To demonstrate that apoE gene polymorphism is
involved in the lipid clearance process and it has great
influence on the lipid level in our body [47,48]. Although
previous study has shown that non-HDL-C concentration
is similar to or better than LDL-C alone in predicting car-
diovascular disease (CVD) incidence [49], in this study, the
results showed that the decrease in HDL-C and elevation
of TG, VLDL-C and LDL-C levels (Table 1) are also the
landmarks of diabetes and CAD development as found in
an earlier study [50]. However, the association of apoE ε4
allele and lipid profile is still controversial [51]. The ε4
allele has been shown to be associated with high concen-
tration of serum TC and LDL-C in Chinese population
[38]. Some studies also showed a significant relationship
between E3/E4 genotype with lower HDL-C and higher
LDL-C concentrations in CAD patients [52] and with
higher TG levels in T2DM patients [48] as compared to
the healthy controls. However, a study in the Tunisian
population has suggested that HDL-C concentration and
other lipid profiles are not associated with apoE gene poly-
morphism in the total population studied, but has proven
that ε4 allele increased LDL-C in type 2 diabetic men [53].
Association of ε4 allele with higher LDL-C and lower
HDL-C levels was only found in type 2 diabetic women in
Spanish population [54] indicating that gender affects the
effect of apoE gene polymorphism. In this study, there is a
mean comparison between E4 carriers and E3/E3 geno-
type in the T2DM and total population studied which
showed a significantly higher VLDL-C, TG and lower
HDL-C levels in E4 carriers (Table 7) similar to the report
of Knouff et al 1999 [15]. Nevertheless, the differences of
lipid profiles were not observed in controls and T2DM
with CAD. This may be due to dietary restrictions in the
controls and lipid-lowering aggressive treatment in T2DM
with CAD. Kolovou et al. 2006 [55] reported that the ε4
allele can increase LDL-C concentrations in the presence
of an atherogenic diet, but a lower fat diet can suppress
this effect. On the other hand, aerobically trained indivi-
duals have high HDL and display enhanced glucose toler-
ance [56]. A lipid-lowering-drug which raises HDL levels
and decrease TG levels delays the onset of T2DM and
reduces the development of atherosclerosis [57]. In addi-
tion, loss of caspase-1 activity which involves the inflam-
matory process in human atherosclerotic vessel has shown
to reduce atherosclerosis lesion formation in Casp1
-/- Apo
E
-/- mice [58]. Another reason for these variations of lipid
profiles might be because of the differences in genetic
background and the prevalence of high oxidative stress in
the studied population. When considering the basis of
gene-gene and gene-environment interactions, as
described above, the polymorphism study at the genome
level might not provide a real picture for development of
diseases in respect to lipid profile. A more robust parallel
study at the protein level, or of other candidate genes, may
be necessary to evaluate the mechanism of T2DM and
CAD development. However, this study will provide a
good starting point for the screening of large populations
before proceeding to the protein level study of apoE and
other candidate genes in various races and, additionally,
including pharmacogenomics study in the future.
Conclusions
This study tentatively supports the fact that variability in
apoE gene locus is associated with diabetes with and
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Page 9 of 11without CAD complication by influencing the plasma
lipid levels that are important risk factors for both
T2DM and CAD. No single factor can give a satisfactory
explanation regarding development of diabetes and CAD
as both diseases are complex diseases. Focusing, there-
fore, on only one risk factor may be less than optimal in
enabling researchers to predict who will develop unto-
ward events in complex diseases like diabetes and CAD.
Nonetheless, our study strongly supported that the apoE
ε4 allele is an independent risk factor for development
of both T2DM and CAD. Moreover, obesity and/or
smoking, conditions associated with high oxidative
stress, can aggravate the progression of both diseases.
Genetic studies can thus provide information that may
help to improve the ability to identify individuals,
families and populations at increased risk, as well as to
improve the clinical management of patients with
T2DM and CAD. Such information may be useful in
developing public health programs reinforcing primary
and secondary prevention for T2DM and CAD. Further-
more, T2DM and CAD patients identified to carry high
risk genotype or allele should be treated aggressively to
prevent the progression of disease.
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